Endometrial hyperplasia pathophysiology

Endometrial hyperplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Endometrial hyperplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Case Studies
Case #1
Endometrial hyperplasia pathophysiology On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Endometrial hyperplasia pathophysiology All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Endometrial hyperplasia pathophysiology
CDC on Endometrial hyperplasia pathophysiology
Endometrial hyperplasia pathophysiology in the news
Blogs on Endometrial hyperplasia pathophysiology
Directions to Hospitals Treating Endometrial hyperplasia
Risk calculators and risk factors for Endometrial hyperplasia pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Soujanya Thummathati, MBBS [2]

Pathophysiology

Pathogenesis

• Endometrial hyperplasia is a condition of excessive proliferation of the endometrial cells (inner lining of the uterus) associated with an increased gland to stroma ratio.
• The proliferative phase is the second phase in normal mentrual cycle when estrogen causes the lining of the uterus to proliferate. As the ovarian follicles mature, they begin to secrete increasing amounts of estradiol, and estrogen. The estrogens initiate the formation of a new layer of endometrium in the uterus, histologically identified as the proliferative endometrium.
• Unopposed oestrogen stimulation (either from an endogenous or exogenous source) is implicated in its pathogenesis